Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 3/20 | 0.44 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2379881 | 1.00 | ALDH1A1 (0.53) | ALDH1A1TSHRNPC1RAB9AEGFR | |
| SCHEMBL1476594 | 0.98 | ALDH1A1 (0.55) | ALDH1A1TSHRNPC1RAB9AEGFR | |
| Phosphoric Acid SCHEMBL10436083 | 0.93 | ALDH1A1 (0.49) | ALDH1A1TSHRNPC1RAB9AEGFR | |
| SCHEMBL4608580 | 0.88 | ALDH1A1 (0.44) | ALDH1A1TSHRNPC1RAB9AKMT2A | |
| Hydrochloric Acid SCHEMBL1642140 | 0.87 | ALDH1A1 (0.57) | ALDH1A1TSHRNPC1RAB9AEGFR | |
| Hydrochloric Acid SCHEMBL866042 | 0.87 | ALDH1A1 (0.57) | ALDH1A1TSHRNPC1RAB9AEGFR | |
| Bromide SCHEMBL14739268 | 0.86 | ACHE (0.45) | ALDH1A1TSHRNPC1RAB9AEGFR | |
| SCHEMBL1476295 | 0.85 | ALDH1A1 (0.59) | ALDH1A1TSHRNPC1RAB9AEGFR | |
| SCHEMBL8921586 | 0.84 | L3MBTL1 (0.50) | ALDH1A1NPC1RAB9ALMNAKDM4E | |
| Methacrylic Acid SCHEMBL28201133 | 0.82 | ALDH1A1 (0.63) | ALDH1A1TSHRNPC1RAB9AEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137690-A1 | USE OF REBOXETINE TO TREAT NARCOLEPSY | AXSOME THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12616702-B2 | Use of reboxetine to treat narcolepsy | AXSOME THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260097040-A1 | USE OF REBOXETINE TO TREAT NARCOLEPSY | AXSOME THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260041691-A1 | USE OF REBOXETINE TO TREAT NARCOLEPSY | AXSOME THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260014165-A1 | USE OF ESREBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS SUCH AS FIBROMYALGIA | AXSOME THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260014163-A1 | USE OF REBOXETINE TO TREAT FIBROMYALGIA | AXSOME THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260014142-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | AXSOME THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250360107-A1 | USE OF MAZINDOL TO TREAT NERVOUS SYSTEM DISORDERS | AXSOME THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-12447155-B2 | Use of reboxetine to treat narcolepsy | AXSOME THERAPEUTICS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4598524-A1 | USE OF MAZINDOL TO TREAT NERVOUS SYSTEM DISORDERS | Axsome Therapeutics, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20070027213-A1 | For therapy of depressive condition | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (CA) | 2007-02-01 | — | — | US | disclosed |
| WO-2007002597-A2 | MODIFIED-RELEASE FORMULATIONS OF A BUPROPION SALT | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2007-01-04 | — | — | WO | disclosed |
| US-7070806-B2 | Controlled release formulations coated with aqueous dispersions of acrylic polymers | PURDUE PHARMA LP (US) | 2006-07-04 | — | — | US | disclosed |
| US-20040054076-A1 | Method for preparing an emulsion with high-viscosity organic phase | RHODIA CHIMIE (FR) | 2004-03-18 | — | — | US | disclosed |
| US-20030198673-A1 | Controlled release formulations coated with aqueous dispersions of acrylic polymers | OSHLACK BENJAMIN (US) | 2003-10-23 | — | — | US | disclosed |
| US-6143353-A | HYDROPHOBIC, STORAGE STABILITY, | PURDUE PHARMA LP (US) | 2000-11-07 | — | — | US | disclosed |
| US-5639476-A | STABILITY | EURO-CELTIQUE, S.A. (LU) | 1997-06-17 | — | — | US | disclosed |
| US-5580578-A | SUSTAIN RELEASED BEADS COATED WITH A COPOLYMERS OF ACRYLIC AND METHACRYLIC ESTERS HAVING QUATERNARY AMMONIUM GROUP; STORAGE STABILITY, WATERPROOFING | EURO-CELTIQUE, S.A. (LU) | 1996-12-03 | — | — | US | disclosed |
| EP-0636366-A2 | Controlled release formulations coated with aqueous dispersions of acrylic polymers | Euroceltique S.A. (LU) | 1995-02-01 | — | — | EP | disclosed |
| US-4737357-A | WATER INSOLUBLE, SWELLING QUATERNARY AMMONIUM POLYMER | ROHM GMBH (DE) | 1988-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360107-A1 | USE OF MAZINDOL TO TREAT NERVOUS SYSTEM DISORDERS | PNMT, COMT, MAOA | EGFR 4863/4885HSP90AA1 3642/4885ALDH1A1 1464/4885 |
| US-20260014163-A1 | USE OF REBOXETINE TO TREAT FIBROMYALGIA | SLC6A4, SLC6A2, CRH | EGFR 4111/4885HSP90AA1 3435/4885ALDH1A1 4659/4885 |
| US-20260014142-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | CYP2D6, CYP3A43, OPRD1 | EGFR 1946/4885HSP90AA1 2026/4885ALDH1A1 1556/4885 |
| US-20030198673-A1 | Controlled release formulations coated with aqueous dispersions of acrylic polymers | ACR, PARG, AMPD1 | EGFR 3486/4885HSP90AA1 491/4885ALDH1A1 778/4885 |
| US-20260097040-A1 | USE OF REBOXETINE TO TREAT NARCOLEPSY | HTR2B, HCRTR2, HTR1B | EGFR 3331/4885HSP90AA1 4751/4885ALDH1A1 3052/4885 |
| US-12616702-B2 | Use of reboxetine to treat narcolepsy | SLC6A4, SLC6A2, SLC18A2 | EGFR 3608/4885HSP90AA1 4212/4885ALDH1A1 3181/4885 |
| US-20260137690-A1 | USE OF REBOXETINE TO TREAT NARCOLEPSY | SLC6A4, SLC6A2, SLC6A11 | EGFR 3859/4885HSP90AA1 4631/4885ALDH1A1 3393/4885 |
| US-20260014165-A1 | USE OF ESREBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS SUCH AS FIBROMYALGIA | FAAH, HTR2B, HTR5A | EGFR 3745/4885HSP90AA1 4626/4885ALDH1A1 4028/4885 |
| US-20070027213-A1 | For therapy of depressive condition | SLC6A2, SLC6A4, HTR5A | EGFR 1673/4885HSP90AA1 1794/4885ALDH1A1 1778/4885 |
| US-12447155-B2 | Use of reboxetine to treat narcolepsy | HCRTR1, HCRTR2, AANAT | EGFR 4865/4885HSP90AA1 4065/4885ALDH1A1 1820/4885 |
| US-20260041691-A1 | USE OF REBOXETINE TO TREAT NARCOLEPSY | SLC6A4, SLC6A2, MAPT | EGFR 4801/4885HSP90AA1 4665/4885ALDH1A1 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.